Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

Elevated incidence of fractures in women with invasive breast cancer.

Edwards BJ, Gradishar WJ, Smith ME, Pacheco JA, Holbrook J, McKoy JM, Nardone B, Tica S, Godinez-Puig V, Rademaker AW, Helenowski IB, Bunta AD, Stern PH, Rosen ST, West DP, Guise TA.

Osteoporos Int. 2016 Feb;27(2):499-507. doi: 10.1007/s00198-015-3246-3. Epub 2015 Aug 21.

PMID:
26294292
2.
3.

Dentin phosphoprotein binds annexin 2 and is involved in calcium transport in rat kidney ureteric bud cells.

Alvares K, Stern PH, Veis A.

J Biol Chem. 2013 May 3;288(18):13036-45. doi: 10.1074/jbc.M112.389627. Epub 2013 Mar 22.

4.

Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.

Edwards BJ, Bunta AD, Lane J, Odvina C, Rao DS, Raisch DW, McKoy JM, Omar I, Belknap SM, Garg V, Hahr AJ, Samaras AT, Fisher MJ, West DP, Langman CB, Stern PH.

J Bone Joint Surg Am. 2013 Feb 20;95(4):297-307. doi: 10.2106/JBJS.K.01181. Review.

5.

How vitamin D works on bone.

Yoshida T, Stern PH.

Endocrinol Metab Clin North Am. 2012 Sep;41(3):557-69. doi: 10.1016/j.ecl.2012.04.003. Epub 2012 May 22. Review.

PMID:
22877429
6.

Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model.

Hu Z, Gupta J, Zhang Z, Gerseny H, Berg A, Chen YJ, Zhang Z, Du H, Brendler CB, Xiao X, Pienta KJ, Guise T, Lee C, Stern PH, Stock S, Seth P.

Hum Gene Ther. 2012 Aug;23(8):871-82. doi: 10.1089/hum.2012.040. Epub 2012 Jun 25.

7.

Regulation of breast cancer-induced bone lesions by β-catenin protein signaling.

Chen Y, Shi HY, Stock SR, Stern PH, Zhang M.

J Biol Chem. 2011 Dec 9;286(49):42575-84. doi: 10.1074/jbc.M111.294595. Epub 2011 Oct 18.

8.

Sex-specific effects of estrogen and androgen on gene expression in human monocyte-derived osteoclasts.

Wang J, Stern PH.

J Cell Biochem. 2011 Dec;112(12):3714-21. doi: 10.1002/jcb.23297.

PMID:
21815190
9.

Dose-dependent differential effects of risedronate on gene expression in osteoblasts.

Wang J, Stern PH.

Biochem Pharmacol. 2011 Apr 15;81(8):1036-42. doi: 10.1016/j.bcp.2011.01.025. Epub 2011 Feb 15.

10.

Antagonist minigenes identify genes regulated by parathyroid hormone through G protein-selective and G protein co-regulated mechanisms in osteoblastic cells.

Wang J, Gilchrist A, Stern PH.

Cell Signal. 2011 Feb;23(2):380-8. doi: 10.1016/j.cellsig.2010.10.008. Epub 2010 Oct 19.

12.

Osteoblast proliferation on hydroxyapatite coated substrates prepared by right angle magnetron sputtering.

Hong Z, Mello A, Yoshida T, Luan L, Stern PH, Rossi A, Ellis DE, Ketterson JB.

J Biomed Mater Res A. 2010 Jun 1;93(3):878-85. doi: 10.1002/jbm.a.32556.

PMID:
19705463
13.

Direct inhibitory and indirect stimulatory effects of RAGE ligand S100 on sRANKL-induced osteoclastogenesis.

Yoshida T, Flegler A, Kozlov A, Stern PH.

J Cell Biochem. 2009 Aug 1;107(5):917-25. doi: 10.1002/jcb.22192.

PMID:
19415676
14.

Rho GTPase signaling and PTH 3-34, but not PTH 1-34, maintain the actin cytoskeleton and antagonize bisphosphonate effects in mouse osteoblastic MC3T3-E1 cells.

Kazmers NH, Ma SA, Yoshida T, Stern PH.

Bone. 2009 Jul;45(1):52-60. doi: 10.1016/j.bone.2009.03.675. Epub 2009 Apr 8.

15.

The small GTPase RhoA is crucial for MC3T3-E1 osteoblastic cell survival.

Yoshida T, Clark MF, Stern PH.

J Cell Biochem. 2009 Apr 1;106(5):896-902. doi: 10.1002/jcb.22059.

16.

Antiresorptive agents and osteoclast apoptosis.

Stern PH.

J Cell Biochem. 2007 Aug 1;101(5):1087-96. Review.

PMID:
17407157
17.

The calcineurin-NFAT pathway and bone: intriguing new findings.

Stern PH.

Mol Interv. 2006 Aug;6(4):193-6.

PMID:
16960140
18.

Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts.

Woo JT, Kawatani M, Kato M, Shinki T, Yonezawa T, Kanoh N, Nakagawa H, Takami M, Lee KH, Stern PH, Nagai K, Osada H.

Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4729-34. Epub 2006 Mar 13.

19.
21.

G alpha12/G alpha13 subunits of heterotrimeric G proteins mediate parathyroid hormone activation of phospholipase D in UMR-106 osteoblastic cells.

Singh AT, Gilchrist A, Voyno-Yasenetskaya T, Radeff-Huang JM, Stern PH.

Endocrinology. 2005 May;146(5):2171-5. Epub 2005 Feb 10.

PMID:
15705779
23.
24.

Cyclosporine A and FK506 induce osteoclast apoptosis in mouse bone marrow cell cultures.

Igarashi K, Hirotani H, Woo JT, Stern PH.

Bone. 2004 Jul;35(1):47-56.

PMID:
15207740
25.

Bone anabolic responses to mechanical load in vitro involve COX-2 and constitutive NOS.

Kunnel JG, Igarashi K, Gilbert JL, Stern PH.

Connect Tissue Res. 2004;45(1):40-9.

PMID:
15203939
26.

MicroCT quantification of in vitro bone resorption of neonatal murine calvaria exposed to IL-1 or PTH.

Stock SR, Ignatiev KI, Foster SA, Forman LA, Stern PH.

J Struct Biol. 2004 Aug;147(2):185-99.

PMID:
15193647
27.

The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells.

Hirotani H, Tuohy NA, Woo JT, Stern PH, Clipstone NA.

J Biol Chem. 2004 Apr 2;279(14):13984-92. Epub 2004 Jan 13.

30.

Regulation of parathyroid hormone-stimulated phospholipase D in UMR-106 cells by calcium, MAP kinase, and small G proteins.

Singh AT, Bhattacharyya RS, Radeff JM, Stern PH.

J Bone Miner Res. 2003 Aug;18(8):1453-60.

31.

In vitro mechanical and cellular responses of neonatal mouse bones to loading using a novel micromechanical-testing device.

Kunnel JG, Gilbert JL, Stern PH.

Calcif Tissue Int. 2002 Dec;71(6):499-507. Epub 2002 Sep 18.

PMID:
12232683
32.

Effects of a selective cyclooxygenase-2 inhibitor, celecoxib, on bone resorption and osteoclastogenesis in vitro.

Igarashi K, Woo JT, Stern PH.

Biochem Pharmacol. 2002 Feb 1;63(3):523-32.

PMID:
11853703
33.

Parathyroid hormone stimulates translocation of protein kinase C isozymes in UMR-106 osteoblastic osteosarcoma cells.

Dossing DA, Radeff JM, Sanders J, Lee SK, Hsieh MR, Stern PH.

Bone. 2001 Sep;29(3):223-30.

PMID:
11557365
34.
36.
38.
40.

Serum insulin-like growth factor-I, insulin-like growth factor binding proteins, and bone mineral content in hyperthyroidism.

Lakatos P, Foldes J, Nagy Z, Takacs I, Speer G, Horvath C, Mohan S, Baylink DJ, Stern PH.

Thyroid. 2000 May;10(5):417-23.

PMID:
10884189
42.
43.

Insulin-like growth factor I production is essential for anabolic effects of thyroid hormone in osteoblasts.

Huang BK, Golden LA, Tarjan G, Madison LD, Stern PH.

J Bone Miner Res. 2000 Feb;15(2):188-97.

44.
47.

Serum interleukin-6 and bone metabolism in patients with thyroid function disorders.

Lakatos P, Foldes J, Horvath C, Kiss L, Tatrai A, Takacs I, Tarjan G, Stern PH.

J Clin Endocrinol Metab. 1997 Jan;82(1):78-81.

PMID:
8989237
48.

Expression and phorbol ester-induced down-regulation of protein kinase C isozymes in osteoblasts.

Sanders JL, Stern PH.

J Bone Miner Res. 1996 Dec;11(12):1862-72.

PMID:
8970887
49.

An in vitro model for studying oral bone loss.

Parkhill JE, Tarjan G, Chai JY, Stern PH.

Northwest Dent Res. 1996 Spring;6(2):17-20. No abstract available.

PMID:
9487923
50.

High calcium enhances responses of UMR-106 osteoblastic cells to epidermal growth factor.

Mancuso VR, Miller DA, Osetek EM, Stern PH.

Northwest Dent Res. 1996 Spring;6(2):6-8. No abstract available.

PMID:
9487920

Supplemental Content

Loading ...
Support Center